Aerpio Pharmaceuticals Inc (ARPO)

NASDAQ
1.16
+0.09(+8.41%)
After Hours
1.16
0.00(0.00%)
- Real-time Data
  • Volume:
    856,205
  • Bid/Ask:
    1.15/1.16
  • Day's Range:
    1.08 - 1.18

ARPO Overview

Prev. Close
1.07
Day's Range
1.08 - 1.18
Revenue
15M
Open
1.08
52 wk Range
0.705 - 2.3
EPS
-0.09
Volume
856,205
Market Cap
54.88M
Dividend (Yield)
N/A (N/A)
Average Vol. (3m)
1,285,381
P/E Ratio
-
Beta
1.68
1-Year Change
58.9%
Shares Outstanding
47,313,338
Next Earnings Date
May 17, 2021
What is your sentiment on Aerpio Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Aerpio Pharmaceuticals Inc News

Aerpio Pharmaceuticals Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyStrong BuyNeutralSell
Technical IndicatorsStrong BuyStrong BuyStrong BuyBuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyNeutralStrong Sell

Aerpio Pharmaceuticals Inc Company Profile

Aerpio Pharmaceuticals Inc Company Profile

Employees
12

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications. Its lead product candidate is AKB-9778. AKB-9778 works by inhibiting VE-PTP, an enzyme that is upregulated in diabetic eye disease and that is responsible for inactivating Tie2. The Company is also developing a bispecific antibody that binds both VEGF and VE-PTP, which is designed to inhibit VEGF activation and activate Tie2. The Company’s pipeline includes the humanized monoclonal antibody, ARP-1536, directed at the same target as subcutaneous AKB-9778.

Read More
  • I read the latest press release, looks like their drug didnt meet primary endpoint, though they hope to check it again during a month. Usually if primary endpoint is not reached then the drug is placebo.
    0
    • Do you think this will go back up anytime soon? Os there bad news for the compmany?
      0
      • do you think he will recover soon?
        0
        • all news is good,
          0
          • what's going on?
            0
            • wt
              0
              • wat the ******is going in after market .. 40 % down ?
                0
                • All Bio shares are down....
                  0
                  • Hmmm seems I was lucky to sell at 1.8
                    0
                    • 😂😂🤦👎
                      0
                      • 1.94 AM EXCELLENT 💪👌👍😊
                        2
                        • ARPO a small stock has given me 22% rise , that too on a day when all others have disappointed . Nova , Mrna , Bntx , Astra , Sanofi ... Seriously I salute to the guys running ARPO. .. its been so stable when all others are horribly unpredictable. ARPO has hd its base value and maintained its 1.5 level and Now its on 1.83 and after market is up again. highly recommended if someone wants to invest 1000 dollars and forget it for a while , I am sure its worth putting your 💰......
                          0
                          • 😊😊😊😊👌👌👌👌
                            0
                            • Yes ... Come on.........well done 💪
                              0
                              • Come on its time to brake through 1.70 Mark and plus 💪
                                0
                                • Buy Buy Buy.....going up 250% on Monday..
                                  0
                                  • bought at 1.47 👍
                                    0
                                    • Buy in Big quantity ... hurry up 👍
                                      1
                                      • I just sold all of mine for $1.52. I didn’t know all of the details. 😭
                                        0
                                      • Tejasvi Gognathanks for the response.
                                        0
                                      • Regina GriffinNano cap Aerpio Pharmaceuticals (NASDAQ:ARPO) jumps 52% premarket on robust volume in reaction to its announcement that the U.S. Army Medical Research and Development Command's Medical Technology Enterprise Consortium has agreed to provide up to $5.1M to support a Phase 2 clinical trial evaluating razuprotafib for the prevention and treatment of acute respiratory distress syndrome (ARDS) in adult patients with moderate-to-severe COVID-19. The company will contribute $2.8M to the study. The trial should be completed by Q1 2021.Razuprotafib (AKB-9778) 
                                        0
                                    • Any tips on how this stock will do today?
                                      0
                                      • pump and dump
                                        0
                                    • Why??
                                      0
                                      • https://finance.yahoo.com/news/aerpio-pharmaceuticals-inc-announces-second-201500148.html?guce_referrer=aHR0cHM6Ly9maW52aXouY29tL3F1b3RlLmFzaHg_dD1BUlBP&guce_referrer_sig=AQAAAM694epP3mfMkRwGi9sNXWBC8MFmSEJWzWkTnX6xs2EC0VBX0VVBFjgdvDdhOykfDvkzQiGphz1idjJrBNULnw9Yyi7p8ztKk79BmqF0vozyYyUunXiadrxWqi133ZPFraP6G5A1etza3kuA5qmimJKYosl2YMD_x8rE8i2BpvWj&_guc_consent_skip=1596619065
                                        0
                                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.